The combination of amlodipine and olmesartan was demonstrated to be superior to monotherapy with either agent in difficult-to-treat hypertensive populations in a subgroup analysis of the registrational trial for this combination therapy. These results were presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension, New Orleans, May 14–17, 2008.
The combination of amlodipine and olmesartan was demonstrated to be superior to monotherapy with either agent in difficult-to-treat hypertensive populations in a subgroup analysis of the registrational trial for this combination therapy. These results were presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension, New Orleans, May 14–17, 2008.
The study examined efficacy among black and Hispanic/Latino patients, patients with diabetes, and patients with high body mass index (BMI) because the blood pressure of these populations is typically hard to control, said Suzanne Oparil, MD, director of the Vascular Biology and Hypertension Program, University of Alabama, Birmingham.
In the randomized, double-blind, placebo-controlled study of 1,940 patients, subgroups were matched for baseline blood pressure and were then randomized to 8 weeks of treatment with 1 of 12 treatment regimens: amlodipine 5 or 10 mg/d as monotherapy; olmesartan 10, 20, or 40 mg/d as monotherapy; 1 of the 6 possible combinations of these doses of amlodipine and olmesartan; or placebo.
In almost all dose comparisons in all ethnic groups, mean reductions in SBP and DBP were significantly greater with the amlodipine/olmesartan combinations than with olmesartan monotherapy. The magnitude of reduction with the combination in black patients (29/16 mmHg) approached that observed in nonblack patients (31/20 mmHg).
Mean reductions in blood pressure were similar between Hispanic/Latino (29/21 mmHg) and non-Hispanic/non-Latino subgroups (30/19 mmHg). In most comparisons, more patients reached target blood pressure with combination therapy than with monotherapy.
The combination was also more effective than monotherapy in patients with diabetes and in patients with high BMI, observed George Bakris, MD, professor of medicine at the University of Chicago.
“The antihypertensive effect of the combination was similar in patients with and without diabetes, and regardless of BMI. If you started on the combination you were more likely to achieve blood pressure goal,” Dr Bakris said.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More